RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

BACKGROUND: To evaluate the objective response rate (ORR) at 2 months of treatment with regorafenib according to RECIST 1.1, Choi, and modified Choi (mChoi) criteria in patients with metastatic colorectal cancer (mCRC). METHODS: Baseline and 2-month contrast-enhanced computed-tomography (CECT) scans...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucidarme, Olivier, Wagner, Mathilde, Gillard, Paul, Kim, Stefano, Bachet, Jean-Baptiste, Rousseau, Benoit, Mazard, Thibault, Louvet, Christophe, Chibaudel, Benoist, Cohen, Romain, Garcia-Larnicol, Marie-Line, Gobert, Aurelien, Henriques, Julie, André, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902493/
https://www.ncbi.nlm.nih.gov/pubmed/31818317
http://dx.doi.org/10.1186/s40644-019-0271-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902493/
https://www.ncbi.nlm.nih.gov/pubmed/31818317
http://dx.doi.org/10.1186/s40644-019-0271-z

Ejemplares similares